[Intravitreal viscoelastic injection for management of combined choroidal and retinal detachments]. / Injection intra-vitréenne de produit viscoélastique pour la gestion des décollements choroïdiens associés aux décollements de rétines.

INTRODUCTION: Combined retinal detachment and choroidal detachment (RDCD) is a serious type of retinal detachment occurring mainly in high myopes, which poses many pre-, intra- and postoperative difficulties that can affect the visual prognosis. MATERIAL AND METHODS: Personal technique used in 8 patients with RDCD, consisting of intravitreal injection (IVI) of a viscoelastic (VE) device 2 to 3 days prior to vitrectomy. RESULTS: Reattachment of the choroid in all patients, with return to normal IOP, allowing vitrectomy to be performed under optimal conditions. DISCUSSION: RDCD often occurs in high myopia, especially in the case of an associated giant tear, the mechanism of which involves severe hypotony, resulting in a vicious cycle including development of the choroidal detachment (CD), partial retinal reattachment, normalization of the IOP, redetachment of the retina, and once again, hypotony. Preoperative viscoelastic IVI can break this vicious cycle and reattach the choroid, often within 24 to 48hours. This thus facilitates RD surgery without the intra- and postoperative technical difficulty of managing the CD. CONCLUSION: Viscoelastic IVI is a simple, safe, inexpensive and reproducible technique for the treatment of CD associated with RD in order to prepare for RD surgery under the usual conditions without a CD.

[Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy]. / Utilisation du bévacizumab dans le traitement de la rétinopathie diabétique proliférative compliquée.

INTRODUCTION: Diabetes is the leading cause of neovascular vitreoretinal proliferation. Several recent publications have appeared showing the efficacy and safety of intravitreal bevacizumab (IVT) in proliferative or complicated diabetic retinopathy (PDR), but with no consensus on the injected dose. We report the results of its use as adjuvant intravitreal injection (IVT) prior to posterior vitrectomy in the setting of complicated PDR. The goal of our work is to evaluate the benefits of and try to establish a protocol for proper use of intravitreal bevacizumab prior to vitrectomy for complicated PDR, so as to incorporate it in the management of this disease. PATIENTS AND METHODS: A prospective comparative study of series of patients hospitalized for severe complicated PDR requiring vitrectomy was spread over one year, from January 2011 to December 2011. Included patients were divided into two groups: group A: receiving an injection preoperatively at a dose of 1.25mg, and group B, which received an injection of bevacizumab at a dose of 0.75mg (with a time to surgery of either less than 3 days, more than 6, or 3 to 6). We analyzed the epidemiological characteristics, data from the initial eye examination and intraoperative complications and follow-up after vitrectomy. RESULTS: Thirty-five patients were included. We noted no significant difference in epidemiological characteristics between group A and B. Sixty percent of patients underwent surgery after a period of three to six days post-IVT. The reduction of neovascularization, decreased risk of bleeding and the facilitation of membrane peeling during surgery were significantly similar between group A and B. No complication related to the molecule and no recurrence, including bleeding, were noted throughout follow-up in both groups. CONCLUSION: We opt for a systematic use of anti-VEGF, particularly bevacizumab prior to all vitrectomies for complicated PDR. A 0.75mg dose at an interval of 3 to 6 days seems to be a good compromise between the desired effect and possible complications that may arise.